U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Slides:



Advertisements
Similar presentations
Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Advertisements

The management of adverse drug reactions I Ralph Edwards
Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 12 Information Basic to Administering Drugs.
15 The Health Record.
Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.
FDA/CVM/OSC/DS Adverse Drug Experience (ADE) Reporting System Division Director: Dr. Lynn Post Team Leaders: Dr. John Baker, ADE Coordinator Dr. Dorothy.
Canine NSAIDs—What Dog Owners Should Know
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
Allergy Awareness Amelia County Public Schools What is an allergy?  An allergy is an abnormal response to a normal substance. This is the body’s attempt.
CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
How and Why Drugs Work Chapter 5
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 
Page Up to Reverse  Employee Health  Page Down to Advance  Employee Health 
Clinical causality assessment I. Ralph Edwards R.H.B Meyboom.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.
H. Lundbeck A/S21-Sep-151 Pharmacovigilance during clinical development SAE reporting, ASUR and PSUR IFF Seminar, 21. February 2007.
 Pharmacology- Study of science that deals with the study of therapeutic agents  Pharmacodynamics- study of the action of drugs on living tissue  Pharmacy-
Investigational New Drug Application (IND)
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
Biotransformation and metabolism
Approved: 9 Jun DoD Leader’s Briefing: Force Health Protection Against Anthrax.
AUA VUR guidelines 2010 Methodology Twenty-one studies met the inclusion criteria (six were prospective), data were extracted and a meta-analysis was.
 1. A care plan is developed for each of the patient's medical conditions being managed with pharmacotherapy.  2. A goal of therapy is the desired response.
DEVELOPING EVIDENCE ON VACCINE SAFETY Susan S. Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics U Penn School of Medicine Global Vaccines.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Effects of Vaccines Thomas D. Overbay, DVM Expedite.
Reading Medication Labels Small Animal Management 130.4(c)2D.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.
Coagulants By: Autum White. Sources   
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
1 TNF Blocker Safety: Lymphoma and Liver Failure Tim Coté MD MPH, Chief, Therapeutics & Blood Safety Branch, DE/OBE/CBER/FDA March 4, 2003.
FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.
CAUSALITY ASSESSMENT OF SUSPECTED AEs Dr. Retesh Kumar Head, Global PhV Department 12/13/2015.
What pharmacovigilance can do for you! relationship assessment is a better concept 24 Nov Dar es Salaam.
Good Pharmacovigilance Practices
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Signal identification and development I.Ralph Edwards.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
The Royal College of Emergency Medicine The Royal College of Emergency Medicine Clinical Audits Initial management of the fitting child Clinical Audit.
The process of drug development. Drug development 0,8 – 1 mld. USD.
Detection & monitoring of ADR
EudraVigilance.
8. Causality assessment:
Safety Reporting Nichol McBee, MPH, CCRP.
IRRITABLE BOWEL SYNDROME
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
What You Should Know About Vaccines in Your Pets
UK Legal Requirement for Notification of Serious Breaches of Good Clinical Practice or The Trial Protocol John Poland, PhD Senior Director, Regulatory.
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
Chapter 19: Medicines and Drugs
Pediatric Inactivated Influenza Vaccine Safety VAERS Reports for Trivalent Inactivated Influenza Vaccine (TIV) in Infants/Toddlers Ann McMahon, MD, MS.
Module 1 Introduction to rotavirus disease and vaccine
Module 1 Introduction to rotavirus disease and vaccine
Module 1 Introduction to rotavirus disease and vaccine
Module 1 Introduction to rotavirus disease and vaccine
Module 1 Introduction to rotavirus disease and vaccine
Adverse Event Analysis
Presentation transcript:

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

FDA/CVM/OSC/DS Adverse Drug Experience Reporting System

Reviewers experience  7/7 have between 8-22 years practice experience and hold current clinical licenses  1/7 has large animal practice experience  6/7 have companion animal and/or exotic experience  6/7 still practice in local practices up to 20- hrs/week

Adverse Drug Experiences Any adverse reaction that occurs when using a drug product Can be mild (itching, sneezing) to severe (death) Include ineffectiveness product defects human safety associated with handling animal drug products

Components of Modified Kramer System 1.Previous Experience (0, -1, +1) 2.Alternative Etiologic Candidate (-1, 0, +2) 3.Timing (-2, 0, +1) 4.Overdose (0, +1) 5.Dechallenge (-1, 0, +1) 6.Rechallenge (–1, 0, +1)

Interpretation of Range  -6 to -1 Remotely drug-related  0 to +2 Possibly drug-related  +3 to +5 Probably drug-related  +6 to +7 Definitely drug-related

Sources of Information Label of approved drug CVM database CVM Freedom of Information Summary Textbooks Journal articles

Sample Adverse Event Report 4 year old neutered mixed breed dog Good health on physical exam Negative heartworm test Received ProHeart 6 injection, labeled dose Vomiting 8 days later

Initial ProHeart 6 Label Vomiting Diarrhea Listlessness Weight loss Seizures Injection site reaction Fever

Previous Experience  For a score of +1  The clinical manifestation is generally recognized to occur in this species at the dosage received (from label adverse reactions, or appearing in the STARS updated database more than 10% of the time, or in published veterinary literature).  For a score of 0  The clinical manifestation is not generally recognized to occur in this species at the dosage received but has been previously reported in veterinary and/or human medicine or:  The drug has limited accumulated clinical experience (time and/or quantity marketed)  For a score of –1  The clinical manifestation is previously unreported and the drug has substantial accumulated clinical experience (time and/or quantity marketed)

Alternative Etiologic Candidate  For a Score of +2  There is no good candidate or no change in a candidate which can explain the clinical manifestation, exclusive of drug administration  For a score of 0  An alternative candidate(s) exists, but not a good one(s) which can well explain the clinical manifestation or:  The clinical manifestation commonly occurs spontaneously in this type of patient and situation, usually in the absence of any recognizable alternative candidate(s)  For a score of –1  There is a good candidate or a change in a candidate which can well explain the clinical manifestation, exclusive of drug administration. (usually identified by a DDX in the comments section of the final report)

Possible Contributing Factors for Vomiting Changes in diet Intestinal parasites Previous history of vomiting Abnormalities in other organs (liver, kidney, pancreas)

Helpful Information Physical exam by veterinarian Medical history Medical evaluation Veterinarian’s opinion Follow Up information

Limited information No known dietary changes One negative stool exam for parasites No blood work done

Timing of Events  For a score of +1  Timing was consistent and as expected for this type of clinical manifestation to this drug  For a score of 0  Do not know what timing to expect  For a score of –2  The timing was inconsistent for this type of clinical manifestation to this drug

Evidence of Overdose  For a score of +1  The clinical manifestation is clearly a dose-related type of manifestation, and there is unequivocal evidence that the amount of drug received was an overdose for this animal  For a score of 0  The clinical manifestation is not a dose-related type of manifestation or there is no evidence of an overdose.

Dechallenge  For a Score of +1  The clinical manifestation disappeared after discontinuation of the suspect drug or administration of a specific antidote  For a Score of 0  Dechallenge difficult, impossible, or inappropriate to assess  A non-specific agent or maneuver (non-antidotal) was administered that was directed against the clinical manifestations and that usually produces the degree and rate of improvement observed in this case  The clinical manifestation is characteristically transient and episodic, and there is no established pattern of the episodes regardless of what occurs after discontinuing the drug  The clinical manifestation is known to be dose-related and the clinical manifestation did not diminish or disappear after the dosage was reduced  For a Score of -1  The clinical manifestation did not diminish or disappear after discontinuation of suspect drug  The clinical manifestation improved without Dechallenge and the improvement cannot be attributed to the development of tolerance

Rechallenge  For a score of +1  The clinical manifestation unequivocally recurred or exacerbated after Rechallenge  For a score of 0  There was no Rechallenge attempted  The clinical manifestation failed to recur or exacerbate on Rechallenge, but the dosage or duration of drug administration on Rechallenge was substantially less than that suspected of causing the original clinical manifestation  Recurrence or exacerbation of the clinical manifestation was impossible to assess because it was progressing or was at a level of severity that any further increase would be difficult to appreciate  For a score of –1  The clinical manifestation failed to recur or exacerbate on Rechallenge

Applied Modified Kramer Algorithm (Vomiting) Previous Experience:+1 Alternative Etiologic Candidate: 0 Timing: +1 Overdose: 0 Dechallenge: 0 Rechallenge: 0 Total Score: +2 “Possibly Drug Related”

Anaphylaxis/Anaphylactoid Reactions Sudden profuse vomiting/diarrhea Swollen head/face Hives Pallor of mucous membranes Collapse

Sample Adverse Event Report for Anaphylaxis 3 year old spayed female Miniature Schnauzer Good health on physical exam Negative heartworm test Received ProHeart 6 injection (labeled dose) and annual distemper vaccination 2 hours later – hives, swollen face, collapse

Applied Modified Kramer Algorithm (Anaphylaxis) Previous Experience:0 Alternative Etiologic Candidate: -1 Timing: +1 Overdose: 0 Dechallenge: 0 Rechallenge: 0 Total Score: 0 “Possibly Drug Related”

Applied Modified Kramer Algorithm (Anaphylaxis) Previous Experience:0 Alternative Etiologic Candidate: 0 Timing: +1 Overdose: 0 Dechallenge: 0 Rechallenge: 0 Total Score: +1 “Possibly Drug Related”

Applied Modified Kramer Algorithm (Anaphylaxis) Previous Experience:+1 Alternative Etiologic Candidate: +2 Timing: +1 Overdose: 0 Dechallenge: 0 Rechallenge: 0 Total Score: +4 “Probably Drug Related”

Causality Assessment Scores for ProHeart 6 Overdose – seldom given, as product is injected by a health professional Dechallenge - can’t be evaluated, as product remains in body for six months Rechallenge - rarely given again if a reaction was recognized after first administration Thus total score can only reach 4, rather than 6 for other drugs.